H. Mildenberger
University of Tübingen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by H. Mildenberger.
Cancer | 2002
Jörg Fuchs; Jana Rydzynski; Dietrich von Schweinitz; Udo Bode; Hartmut Hecker; P. Weinel; D. Bürger; Dieter Harms; Rudolf Erttmann; Karl Oldhafer; H. Mildenberger
In the past 20 years, a dramatic improvement in the prognosis of patients with hepatoblastoma (HB) has been achieved by combining surgery with chemotherapy in several national and international trials. A worldwide, unsolved problem remains the treatment of patients with advanced or metastatic HB.
Journal of Pediatric Surgery | 1995
D. von Schweinitz; Hartmut Hecker; Dieter Harms; Udo Bode; P. Weinel; D. Bürger; R. Erttmann; H. Mildenberger
Clinical data and tumor histology of 37 patients with advanced and/or metastatic hepatoblastoma (32 stage III and 5 stage IV) treated according to the protocol of the German Cooperative Pediatric Liver Tumor Study HB-89 from 1988 to 1992 were studied for prognostic factors. Twenty-three patients (73%) were free of tumor 9 months to 5 years (median, 36 months) after treatment, whereas 4 experienced progressive disease, 7 had local relapse, and 3 had recurrent metastases. None of 2 patients with primary lymph node involvement or 5 with primary metastases remained disease-free. Chemotherapy with ifosfamide, cisplatin, and adriamycin was effective in reduction of tumor to resectability in 33 (89%) patients. Drug resistance developed in 6 of 11 patients treated with four or more courses of chemotherapy as could be shown by monitoring of serum-alpha-fetoprotein (AFP) and serial investigations of tumor expansion with sonography and computed tomographic (CT) scan. Only 1 of these patients survived after a liver transplantation. Completeness of tumor resection at second- or third-look laparotomy was significantly related to disease-free survival (P < .0001). Patients with initial serum-AFP values < 100 ng/mL or > 1,000,000 ng/mL had a worse outcome than those with immediate levels (P = .044). The rate of decrease of serum-AFP during chemotherapy was significantly related to prognosis (P = .003). Growth pattern of tumor within the liver (ie, defined nodes versus diffusely disseminated) (P = .011) and vascular tumor invasion (P = .026) were valuable prognostic factors, whereas tumor volume, local infiltration of surrounding tissue, histological subtypes, and epithelial differentiation were not significantly related to the outcome.(ABSTRACT TRUNCATED AT 250 WORDS)
European Journal of Cancer | 1997
D. von Schweinitz; D.J Byrd; Hartmut Hecker; P. Weinel; Udo Bode; D. Bürger; R. Erttmann; Dieter Harms; H. Mildenberger
European Journal of Pediatric Surgery | 1995
D. von Schweinitz; S. Glüer; H. Mildenberger
European Journal of Cancer | 1994
D. von Schweinitz; P. Wischmeyer; Ivo Leuschner; Dietmar Schmidt; Ch. Wittekind; Dieter Harms; H. Mildenberger
European Journal of Pediatric Surgery | 2002
Jörg Fuchs; J. Rydzynski; H. Hecker; H. Mildenberger; Bürger D; D. Harms; Dietrich von Schweinitz
Klinische Padiatrie | 1999
Jörg Fuchs; Udo Bode; Dietrich von Schweinitz; P. Weinel; R. Erttmann; Dieter Harms; H. Mildenberger
International Journal of Cancer | 1993
Dietrich von Schweinitz; Martin Hadam; Karl Welte; H. Mildenberger; Torsten Pietsch
Klinische Padiatrie | 1994
D. von Schweinitz; D. Bürger; Udo Bode; P. Weinel; R. Erttmann; Hartmut Hecker; H. Mildenberger
European Journal of Pediatric Surgery | 1994
A. Reiter; W. Zimmermann; M. Zimmermann; D. von Schweinitz; H. Riehm; H. Mildenberger